| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2025-058 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情形。 2、本次股东大会不涉及变更前次股东大会决议。 3、本次股东大会以现场及网络投票相结合的方式召开。 4、为尊重中小投资者利益，提高中小投资者对公司股东大会决议事项的参 与度，本次股东大会对审议影响中小投资者利益的重大事项时进行单独计票，中 小投资者是指除上市公司董事、监事、高级管理人员以及单独或者合计持有公司 5%以上股份的股东以外的其他股东。 一、会议召开情况 1、会议召集人：公司董事会 2、会议主持人：董事长杨勇萍先生 3、会议召开方式：本次股东大会采取现场表决与网络投票相结合的方式 司法》《证券法》等相关法律法规及《公司章程》的规定。 二、会议出席情况 1、出席会议股东的总体情况 4、会议召开的日期、时间 （1 ...

上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 52341668 传真/Fax: +86 21 52341670 网址/Website: http://www.grandall.com.cn 一、 本次股东大会召集、召开的程序 1、本次股东大会的召集 经本所核查，公司本次股东大会由 2025 年 4 月 25 日召开的公司第五届董事会第二十五 次会议提议召开，公司董事会负责召集。公司董事会于 2025 年 4 月 28 日在巨潮资讯网 （http://www.cninfo.com.cn/）和深圳证券交易所网站上以公告形式刊登了《上海雪榕生物科技 关于上海雪榕生物科技股份有限公司 2024年年度股东大会的法律意见书 致：上海雪榕生物科技股份有限公司 国浩律师（上海）事务所（以下简称"本所"）接受上海雪榕生物科技股份有限公司（以 下简称"公司"）委托，指派本所律师出席公司 2024 年年度股东大会（以 ...

Meeting Overview - The company will hold the 2024 Annual General Meeting (AGM) on May 23, 2025, at 14:30, combining both in-person and online video formats [1] - The network voting will take place on the same day, with specific time slots for voting through the Shenzhen Stock Exchange (SZSE) trading system and internet voting system [1][2] Voting Procedures - Shareholders can participate in the AGM either by attending in person or by authorizing a proxy to attend [2] - The voting will be conducted through the SZSE trading system and internet voting system, with only one voting method allowed per shareholder for each proposal [2][7] Registration and Attendance - The record date for shareholders to attend the AGM is May 19, 2025, and all ordinary shareholders registered by the close of trading on that date are eligible to attend [2] - Specific documentation is required for both shareholders and their proxies to register for the meeting [4] Agenda Items - The meeting will review several proposals, including the first grant of restricted stock incentive plans and the cancellation of unvested restricted stocks [2][3] - Independent directors will present their annual reports, and the board will report on the independence of the independent directors [3] Contact Information - The company has provided contact details for inquiries related to the AGM, including addresses, phone numbers, and email [4]

2、股东大会召集人：公司董事会。 | 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2025-057 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 关于召开 2024 年年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）第五届董事会第二十 五次会议审议通过了《关于召开 2024 年年度股东大会的议案》，决定于 2025 年 5 月 23 日召开公司 2024 年年度股东大会，具体内容详见公司公布在中国证监会 指定创业板信息披露网站巨潮资讯网的《关于召开 2024 年年度股东大会通知的 公告》（公告编号：2025-051）。现将本次股东大会的有关事项提示如下： 一、本次股东大会召开的基本情况 1、股东大会届次：2024 年年度股东大会。 5、会议的召开方式：本次股东大会采取现场表决与网络投票相结合的方式。 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章 ...

Market Performance - The plant-based meat concept index rose by 3.14%, ranking 6th among concept sectors, with 21 stocks increasing in value, including Xue Rong Biological and Zu Ming Co., both hitting the daily limit [1] - Notable stock performances include Dong Bao Biological, Ling Ge Technology, and Hao Xiang Ni, which increased by 5.22%, 4.60%, and 3.52% respectively [1] Capital Flow - The plant-based meat sector saw a net inflow of 245 million yuan, with 10 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow [1] - Leading the net capital inflow was Xue Rong Biological with 114 million yuan, followed by Zu Ming Co. with 61.62 million yuan, Hao Xiang Ni with 48.93 million yuan, and Shuang Hui Development with 19.72 million yuan [1] Capital Inflow Ratios - The top stocks by net capital inflow ratio include Zu Ming Co. at 31.31%, Xue Rong Biological at 16.69%, and Dong Bao Biological at 11.14% [2]

证券代码：300511 证券简称：雪榕生物 公告编号：2025-056 债券代码：123056 债券简称：雪榕转债 上海雪榕生物科技股份有限公司 关于2024年度担保额度预计的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 上海雪榕生物科技股份有限公司（以下简称"公司"）于2024年4月25日召开了第 五届董事会第九次会议和第五届监事会第七次会议，于2024年5月17日召开了2023年 年度股东大会，分别审议通过了《关于2024年度担保额度预计的议案》。为满足公 司及子公司生产经营和业务发展需要，确保资金流畅通，公司在保证规范运营和风 险可控的前提下，预计在2024年度为子公司向银行或其他金融机构申请融资业务时 提供总额度不超过人民币21.10亿元（含本数）的担保，其中，公司为资产负债率低 于70%的子公司提供担保额度为6.5亿元人民币（含本数），为资产负债率高于70% 的子公司提供担保额度为14.6亿元人民币（含本数），担保额度有效期限自公司2023 年年度股东大会审议通过之日起至2024年年度股东大会召开之日止，上述担保额度 在 ...

Group 1: Financial Performance - The company has disclosed its financial report, and investors are encouraged to review it for details on profitability [2] - The company aims to reduce costs and improve efficiency to drive future profit growth amidst a competitive environment [2] Group 2: Industry Overview - China is a major producer and consumer of edible mushrooms, with government support for the industry's development [3] - Despite increased competition leading to lower sales prices and declining industry profitability, long-term trends suggest a positive outlook for the industry as it may help eliminate excess capacity and improve overall market conditions [3] Group 3: Company Strategy - The company plans to maintain stable production while focusing on operational improvements to navigate the challenging market [2] - The company's gross margin trends are generally in line with industry peers, indicating no significant deviation from competitors [2]

Core Viewpoint - The NMN concept sector has shown a significant increase of 2.07%, leading among various concept sectors, with notable stocks like Xiwang Food and Jindawei reaching their daily limit up [1][2]. Group 1: Sector Performance - The NMN concept sector ranked first in daily gains, with 21 stocks rising, including Xiwang Food and Jindawei, which hit the daily limit up [1]. - Other sectors with positive performance include synthetic biology (2.05%), pet economy (1.98%), and dairy industry (1.67%) [2]. - The sectors with the largest declines include Huawei Pangu (-3.76%) and DRG/DIP (-3.30%) [2]. Group 2: Capital Flow - The NMN concept sector experienced a net inflow of 436 million yuan, with 17 stocks receiving net inflows, and 6 stocks exceeding 30 million yuan in net inflow [2]. - Jindawei led the net inflow with 155.31 million yuan, followed by Xiwang Food (99.59 million yuan) and Zhejiang Medicine (50.07 million yuan) [2][3]. - The net inflow ratios for Jindawei, Xiwang Food, and Zhejiang Medicine were 29.36%, 27.57%, and 15.18%, respectively [3]. Group 3: Individual Stock Performance - Jindawei saw a daily increase of 9.99% with a turnover rate of 4.82% and a net inflow of 155.31 million yuan [3]. - Xiwang Food increased by 10.07% with a turnover rate of 10.94% and a net inflow of 99.59 million yuan [3]. - Other notable performers include Yabenn Chemical (4.96% increase) and Yikang Pharmaceutical (3.02% increase) [3].

Core Viewpoint - The company has decided not to exercise the early redemption rights for its convertible bonds, "Xue Rong Convertible Bonds," despite triggering the conditional redemption clause due to stock price performance [1][2][8]. Group 1: Convertible Bond Basic Information - The company issued 5,850,000 convertible bonds on June 24, 2020, with a total fundraising amount of RMB 585 million [2][3]. - The bonds were listed on the Shenzhen Stock Exchange on July 24, 2020, under the code "123056" [3]. - The conversion period for the bonds is from January 4, 2021, to June 23, 2026 [3]. Group 2: Conditional Redemption Clause - The conditional redemption clause allows the company to redeem the bonds if the stock price remains above 120% of the conversion price for at least 15 out of 30 consecutive trading days [7][8]. - The current conversion price is set at RMB 4.10 per share, with the stock price needing to exceed RMB 4.92 to trigger the redemption [1][7]. Group 3: Decision on Redemption - The board of directors has resolved not to exercise the early redemption rights for the next three months, from May 14, 2025, to August 13, 2025 [2][8]. - If the redemption conditions are met again after August 13, 2025, the board will reassess the situation and make a decision accordingly [2][8]. Group 4: Shareholder Transactions - The actual controller, major shareholders, and senior management have not traded the convertible bonds in the six months prior to the redemption conditions being met and have no plans to reduce their holdings in the next six months [8][9]. Group 5: Sponsor's Review Opinion - The sponsor has confirmed that the decision not to redeem the bonds has been approved by the board and complies with relevant regulations and the terms outlined in the offering document [9].

证券代码：300511 证券简称：雪榕生物 公告编号：2025-054 债券代码：123056 债券简称：雪榕转债 上海雪榕生物科技股份有限公司 第五届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海雪榕生物科技股份有限公司 董事会 本议案以 7 票同意，0 票反对，0 票弃权获得通过。 三、备查文件 特此公告。 下简称"公司"）会议室召开，采取现场和通讯相结合的方式进行表决。 本次董事会。 及《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 自 2025 年 3 月 27 日至 2025 年 5 月 13 日，雪榕生物股票已有十五个交易日 的收盘价不低于"雪榕转债"当期转股价格（即 4.10 元/股）的 120%（即 4.92 元/ 股）。根据《上海雪榕生物科技股份有限公司 2020 年度向不特定对象发行可转 换公司债券并在创业板上市募集说明书》中有条件赎回条款的相关规定，已触发 了"雪榕转债"的有条件赎回条款（即：在转股期内，如果公司股票在任何连续 结合当前的市场情况及公司自身实际情况，公 ...